Cannabinoid receptor compounds and uses thereof
Patent Information
- Application Number
- CN202380030150.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-15
- Filing Date
- 2023-07-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing cannabinoid receptor antagonists often cause severe psychiatric side effects when blocking central signals, and are not selective enough for CB2 receptors, making drug development challenging.
A compound was developed that has good CB1 receptor binding ability and inverse agonistic activity while barely affecting CB2 receptors. The compound structure was optimized to reduce central nervous system side effects and improve selectivity for CB1.
It achieves the expected pharmacological activity while reducing CB2 receptor-related side effects. The compound has the advantages of short synthesis route, convenient preparation process and simple product post-processing.
Smart Images

Figure CN118984824A_ABST
Abstract
Description
Cannabinoid receptor compounds and uses thereof
[0001] This application claims priority to a prior application filed with the State Intellectual Property Office of China on July 15, 2022, with patent application number 202210837596.5, entitled “Cannabinoid Receptor Compounds and Uses Thereof.” The entire text of that prior application is incorporated herein by reference. Technical Field
[0002] The present invention belongs to the field of medical technology, and in particular relates to cannabinoid receptor compounds and uses thereof. Background Art
[0003] Cannabinoid receptors CB1 and CB2 are key components of the endocannabinoid system and the primary target of D9-tetrahydrocannabinol (D9-THC). D9-THC is a psychoactive chemical extracted from cannabis with a wide range of therapeutic uses (Lemberger, 1980). Activated by the lipids of THC, cannabinoid receptor 1 (CB1) is associated with psychoactive, neuromodulatory, and analgesic effects. Cannabidiol (CBD) has garnered widespread attention for its pharmacological effects or benefits, including neuroprotective, analgesic, anti-inflammatory, antioxidant, and antiepileptic properties. Endocannabinoid receptors are highly expressed in the central nervous system, adipocytes, hepatocytes, and musculoskeletal tissues. Endocannabinoid agonists include anandamide (AEA) and 2-arachidonoyl glycerol (2-AG). CB1 and CB2 play important roles in a variety of physiological processes, including appetite, pain perception, memory, and immune regulation (Manuel Guzmán, Nat Rev Cancer. 2003 Oct; 3(10): 745-55). The two cannabinoid receptors share 44% overall sequence homology and 68% sequence similarity in the transmembrane region (Munro et al., 1993). However, they have different tissue distributions and play different functions in the endocannabinoid system, with CB1 and CB2 being primarily expressed in the central nervous system and immune system, respectively. Due to the high sequence similarity between the two, the development of therapeutic applications is limited by the selectivity of the individual targets.
[0004] Rimonabant, developed by Sanofi-Synthelabo of Saint-Pierre, France, is the world's first cannabinoid receptor type 1 (CB1) inhibitor weight loss drug. It has a strong weight loss effect, enhances insulin sensitivity, improves lipid metabolism, and has some efficacy in assisting smoking cessation. It was approved for marketing in the European Union in 2006 as a new weight loss drug.
[0005] Rimonabant not only effectively reduces weight but also simultaneously targets two other risk factors associated with heart disease: smoking and high cholesterol. Since obese patients often suffer from heart damage, treatment with this drug will offer greater benefits. Therefore, rimonabant has become one of the most promising weight loss drugs currently available. Rimonabant can reduce visceral fat and improve fatty liver index. However, clinical and post-marketing studies have found that rimonabant can increase serious psychiatric adverse reactions, such as depression and anxiety, and also increase the risk of suicide in users. Consequently, rimonabant was withdrawn from the European market. From new drug discovery to market launch, this is a target with proven clinical efficacy. However, small molecule drugs can have serious central nervous system side effects. By leveraging the characteristics of this target, large molecule drugs can be developed that retain efficacy while reducing central nervous system side effects, potentially becoming best-in-class drugs. In terms of antagonist drug development, obesity, Prader-Willi Syndrome (PWS), type 1 diabetes (T1D), non-alcoholic fatty liver disease (NASH), fibrosis, diabetic nephropathy (ND), diabetic gastroparesis, tobacco dependence and high cholesterol are all indications that can be developed for this target in the future.
[0006] The initial phase of this project focused on developing peripherally restricted small molecule inverse agonists. BBB-crossing small molecule antagonists suppress appetite and promote feeding by blocking receptors in the brain and peripheral adipose tissue, but blocking central signaling can cause serious psychiatric side effects. A 2017 article published in J Clin Invest demonstrated that adipocyte CB1 deficiency prevented diabetic indigestion and metabolic disorders by peripherally knocking out CB1 receptors, indicating that peripheral CB1 blockade has reasonable biological significance in reducing mouse body weight and liver fat. Compared to BBB-crossing small molecules, developing peripherally restricted small molecule drugs that retain efficacy and reduce central nervous system side effects is expected to be the best option. In terms of drug development, obesity, PWS, T1D, NASH, diabetic nephropathy, fibrosis, and other conditions are all potential future indications for this target.
[0007] Summary of the Invention
[0008] To improve the above technical problems, the present invention provides a compound represented by the following formula I, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof,
[0009] wherein X is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 6-20 Aryl, 5-20 membered heteroaryl, C 3-20Cycloalkyl, 3-20 membered heterocyclic group;
[0010] Ra are independently selected from oxo (=O), CN, halogen, amino, nitro, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynyl;
[0011] n is 1 or 2;
[0012] Ring A is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rb: C 6-20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkenyl C 6-20 Aryl, 3-20 membered heterocyclic group and C 6-20 aryl;
[0013] Rb are independently selected from CN, amino, nitro, halogen, C 1-12 Alkyl, halogenated C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 alkoxy;
[0014] Z is N, CH or C;
[0015] --Y-- is absent or represents an ethenylene group optionally substituted with Rb, provided that, when Z is N or CH, --Y-- is absent;
[0016] R 1 Selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc: C6- 20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group;
[0017] Rc are independently selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogen, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 3-20 Cycloalkyl, CN, amino, nitro;
[0018] R 2 Indicates -NHRd, and
[0019] Rd independently represent H, unsubstituted or carboxy-substituted C 1-12 Alkyl, C 1-12 Alkylamino, amino, nitro, CN, C 1-12 Alkylcarbonylamino.
[0020] According to some embodiments of the present invention, X may be selected from the following groups which are unsubstituted or optionally substituted with one, two or more Ra: C 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group;
[0021] Ra can be independently selected from ═O, CN or C 1-6 alkyl;
[0022] n is 1 or 2;
[0023] Ring A may be selected from the following ring systems which are unsubstituted or optionally substituted with one, two or more Rb: C 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Cycloalkenyl C 6-12 Aryl, 3-12 membered heterocyclic group and C 6-12 aryl;
[0024] Rb can be selected from halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 alkoxy;
[0025] Z can be N, CH or C;
[0026] --Y-- may be absent or represent an ethenylene group optionally substituted with Rb, provided that, when Z is N or CH, --Y-- is absent;
[0027] R 1 Can be selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc: C 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, 5-12 membered heteroaryl and C 6-12 Aryl, 3-12 membered heterocyclic group and C 6-12 aryl;
[0028] Rc can be independently selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogen, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 3-20 Cycloalkyl, CN;
[0029] R 2 Can represent -NHRd, and / or
[0030] Rd independently represent H, unsubstituted or carboxy-substituted C 1-6Alkyl, C 1-6 Alkylamino, amino, nitro, CN, C 1-6 Alkylcarbonylamino.
[0031] According to some embodiments of the present invention, in the compound represented by Formula I, the carbon atom connected to X may be a chiral carbon atom, and thus the compound represented by Formula I has the structure represented by Formula Ia or Formula Ib below:
[0032] Among them, X, ring A, n, Z, --Y--, R 1 、R 2 As defined in Formula I.
[0033] According to some embodiments of the present invention, in the compound represented by Formula I, n is 1 or 2, --Y-- is absent, and Z is N. Therefore, the compound represented by Formula I has the structure represented by Formula Ic or Formula Id below:
[0034] Among them, X, ring A, R 1 、R 2 As defined in formula I;
[0035] Alternatively, in the compound represented by Formula I, n is 1, --Y-- represents a vinylene group optionally substituted by Rb, and Z is C, so the compound represented by Formula I has the structure represented by the following Formula Ie:
[0036] Among them, X, Rb, R 1 、R 2 As defined in Formula I, Ring A' represents C 3-20 Cycloalkyl ring or 3-20 membered heterocyclic ring, m represents 0, 1, 2 or 3.
[0037] Preferably, in the compound represented by Formula 1e, Rb replaces the ring A', so the compound represented by Formula 1e has the structure represented by the following Formula If:
[0038] Among them, X, Rb, R 1 、R 2 , Ring A' and m are as defined in Formula le.
[0039] Preferably, in the compound represented by Formula If, ring A' is a benzene ring, and Rb replaces ring A', so the compound represented by Formula If has the structure represented by the following Formula Ig:
[0040] Among them, X, Rb, R 1 、R 2 and m are as defined in Formula Ie or If.
[0041] According to some embodiments of the present invention, X is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: phenyl, cyclohexyl, pyridyl, dihydropyridyl; Ra independently represents oxo, CN, C 1-6 Alkyl (eg, methyl or ethyl).
[0042] According to some embodiments of the invention, X is selected from phenyl, cyclohexyl, pyridin-2-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, or 4-cyanophenyl.
[0043] According to some embodiments of the present invention, ring A is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rb: five-membered or six-membered heteroaryl, phenyl, 2,3-dihydro-1H-indenyl, 2,3-dihydrobenzofuranyl; Rb independently represents C 1-6 Alkyl, C 1-6 Alkoxy, halogen or halogenated C 1-6 alkyl.
[0044] According to some embodiments of the present invention, ring A is selected from the following groups which are unsubstituted or optionally substituted with one, two or more Rb: pyridyl, pyrimidinyl, phenyl, 1H-imidazolyl, thiazolyl, 2,3-dihydro-1H-indenyl, 2,3-dihydrobenzofuranyl; Rb independently represent fluorine, chlorine, difluoromethyl, trifluoromethyl, methyl, methoxy.
[0045] According to some embodiments of the invention, ring A is selected from 5-chloropyridin-2-yl, 5-methylpyridin-2-yl, 6-methylpyridin-3-yl, 3-fluoro-5-chloropyridin-2-yl, 5-chloropyrimidin-2-yl, 6-difluoromethylpyridin-3-yl, 6-trifluoromethylpyridin-3-yl, 5-trifluoromethylpyridin-2-yl, 3-chloropyridin-6-yl, phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 1-methyl-2-trifluoromethyl-1H-imidazol-4-yl, 2-trifluoromethylthiazol-5-yl, 2,3-dihydro-1H-inden-5-yl, 2,3-dihydrobenzofuran-5-yl.
[0046] According to some embodiments of the present invention, R 1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc: C 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Bicycloalkyl, 5-12 membered heterocyclic group;
[0047] Rc can be independently selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogen, halogenated C 1-12 Alkyl, halogenated C 1-12Alkoxy, C 3-20 Cycloalkyl, CN.
[0048] According to some embodiments of the present invention, R 1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc: phenyl, pyridyl, bicyclo[1.1.1]pentyl, 1H-pyrazolyl, thiazolyl, 2,3-dihydrobenzofuranyl, pyrazolo[1,5-a]pyridinyl, Rc being independently selected from chlorine, fluorine, cyclopropyl, CN, trifluoromethyl, difluoromethyl, tert-butyl, methoxy, methyl, ethyl, trifluoromethoxy.
[0049] According to some embodiments of the present invention, R 1 Selected from 4-chlorophenyl, 4-fluorophenyl, 4-cyclopropylphenyl, 4-cyanophenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-fluoro-3-trifluoromethylphenyl, 4-difluoromethylphenyl, 4-trifluoromethoxyphenyl, 4-tert-butylphenyl, 6-trifluoromethylpyridin-3-yl, 6-methoxypyridin-3-yl, 5-trifluoromethylpyridin-2-yl, 6-chloropyridin-3-yl, 3-trifluoromethylbicyclo[1.1.1]pentan-1-yl, 1-ethyl-1H-pyrazol-4-yl, 2-trifluoromethylthiazol-5-yl, 2,3-dihydrobenzofuran-5-yl, pyrazolo[1,5-a]pyridin-5-yl.
[0050] According to some embodiments of the present invention, R 2 Indicates -NHRd, wherein Rd independently represents H, unsubstituted C 1-6 Alkyl, amino, C 1-6 Alkylcarbonylamino, carboxyl C 1-12 Alkyl; in some embodiments, Rd independently represent H, methyl, amino, acetylamino, 2-carboxymethyl-4-methylpentan-1-yl, pivaloylamino.
[0051] According to some embodiments of the present invention, the compound represented by Formula I has a structure represented by Formula If, wherein Ring A' represents a 2,3-dihydrofuran ring or a benzene ring, and Rb independently represents C 1-6 Alkoxy, halogen or halogenated C 1-6 Alkyl preferably independently of one another represents fluorine, chlorine or methoxy.
[0052] According to some embodiments of the present invention, the compound represented by Formula I has a structure represented by Formula Ig, wherein Rb independently represents C 1-6 Alkoxy, halogen or halogenated C 1-6 Alkyl preferably independently of one another represents fluorine, chlorine or methoxy.
[0053] According to some embodiments of the present invention, the compound represented by formula I can be selected from the following compounds:
[0054] The present invention also provides a pharmaceutical composition comprising at least one of the compound represented by Formula I, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof.
[0055] According to an embodiment of the present invention, the pharmaceutical composition is used to prevent or treat a disease or condition mediated by cannabinoid receptors. Preferably, the pharmaceutical composition is used to prevent or treat a disease or condition mediated by cannabinoid receptor type 1 (CB1).
[0056] According to an embodiment of the present invention, the cannabinoid receptor-mediated disease or disorder is selected from the group consisting of obesity, PWS syndrome, diabetes, non-alcoholic steatohepatitis, fibrosis, diabetic nephropathy, diabetic gastroparesis, tobacco dependence, and high cholesterol.
[0057] According to an embodiment of the present invention, the pharmaceutical composition further comprises one, two or more pharmaceutically acceptable excipients.
[0058] According to an embodiment of the present invention, the pharmaceutically acceptable excipient is selected from one, two or more of physiologically or pharmaceutically acceptable carriers, diluents, vehicles and / or excipients.
[0059] According to an embodiment of the present invention, suitable routes of administration of the pharmaceutical composition include but are not limited to oral, rectal, topical, buccal, parenteral, intramuscular, intradermal, intravenous and transdermal administration.
[0060] According to an embodiment of the present invention, the pharmaceutical composition is for oral administration, and the pharmaceutical composition can be in the form of tablets, pills, lozenges, sugar-coated tablets, capsules, and the like.
[0061] According to an embodiment of the present invention, the pharmaceutical composition is used for external topical administration, and the pharmaceutical composition can be an ointment, cream, paste, tincture, plaster, gel, film, paint, aerosol, spray, foam, micro sponge, etc.
[0062] The present invention provides the compound represented by the above formula I, its racemate, stereoisomer, tautomer, isotope-labeled product, solvate, polymorph, pharmaceutically acceptable salt or prodrug, or the use of the pharmaceutical composition in the preparation of a medicament for treating or preventing cannabinoid receptor-mediated diseases.
[0063] The present invention also provides a method for treating or preventing diseases or conditions mediated by cannabinoid receptors, preferably cannabinoid receptor type 1 (CB1), or alleviating symptoms thereof, comprising administering to an individual in need thereof a preventively or therapeutically effective amount of a compound of formula I of the present invention, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition of the present invention.
[0064] According to an embodiment of the present invention, the cannabinoid receptor-mediated disease or disorder is selected from the group consisting of obesity, PWS syndrome, diabetes, non-alcoholic steatohepatitis, fibrosis, diabetic nephropathy, diabetic gastroparesis, tobacco dependence, and high cholesterol.
[0065] In all administration methods of the compound represented by formula I of the present invention, the daily dosage is 0.01 to 200 mg / kg body weight.
[0066] According to embodiments of the present invention, the dosage regimen can be adjusted to provide the optimal desired response. For example, a single oral dose can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It should be noted that dosage values can vary with the type and severity of the condition to be alleviated and can include single or multiple doses. It is further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering the composition or supervising the administration of the composition. Beneficial effects
[0067] The compounds of the present invention exhibit excellent binding affinity and inverse agonist activity at human CB1 receptors, while exhibiting virtually no inverse agonist activity at human CB2 receptors. Consequently, the compounds exhibit excellent selectivity for CB1, achieving the desired pharmacological activity while reducing CB2 receptor-related side effects. Furthermore, the compounds of the present invention have the advantages of a short synthetic route, an easy preparation process, and simple product post-processing.
[0068] Definition and Description
[0069] Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs.
[0070] In this article, the wavy line Truncated chemical bonds indicate the attachment sites of the corresponding groups.
[0071] "More" means three or more.
[0072] The term "optional" (or "optionally", "optionally") in the general formula definition means the case of being substituted by zero, one or more substituents, for example, "optionally substituted by one, two or more R" means that it may not be substituted by R (unsubstituted) or may be selectively substituted by one, two or more R.
[0073] The term "halogen" includes F, Cl, Br or I.
[0074] The term "vinylene" is generally understood in the art and includes the following structures:
[0075] When the numerical ranges described in the specification and claims of this application are defined as "integers" or are generally understood as "integers" according to common understanding in the art, they should be understood to include both endpoints of the range as well as every integer within the range. For example, when "0-12" represents the number of carbon atoms, it should be understood to include every integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.
[0076] The term "C 1-12 "Alkyl" is understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1 to 12 carbon atoms. For example, "C 1-6 The term "alkyl" refers to straight-chain and branched alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, or the like or isomers thereof.
[0077] The term "C 1-12 "Alkoxy" should be understood as -OC 1-12 Alkyl, where C 1-12 Alkyl has the above definition.
[0078] The term "C 3-20"Cycloalkyl" should be understood to mean a saturated monovalent monocyclic, bicyclic hydrocarbon ring or polycyclic hydrocarbon ring (also called condensed hydrocarbon ring) having 3-20 carbon atoms. Bicyclic or polycyclic cycloalkyl groups include paracyclic cycloalkyl, bridged cycloalkyl and spirocyclic cycloalkyl; the paracyclic refers to a condensed ring structure formed by two or more cyclic structures sharing two adjacent ring atoms (i.e., sharing a bond). The bridged ring refers to a condensed ring structure formed by two or more cyclic structures sharing two non-adjacent ring atoms. The spirocyclic refers to a condensed ring structure formed by two or more cyclic structures sharing one ring atom. For example, the C 3-20 The cycloalkyl group may be C 3-8 Monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or C 7-12 Cycloalkyl, such as decahydronaphthalene ring; can also be C 7-12 Bridged ring cycloalkyl, such as norbornane, adamantane, bicyclo[2,2,2]octane. Correspondingly, the term "cycloalkenyl" refers to a cycloalkyl group containing one or more double bonds within the ring.
[0079] The term "3-20 membered heterocyclyl" means a partially saturated or unsaturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1 to 5 heteroatoms independently selected from N, O and S, preferably a "3-10 membered heterocyclyl". The term "3-10 membered heterocyclyl" means a partially saturated or unsaturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1 to 5, preferably 1 to 3 heteroatoms selected from N, O and S. The heterocyclyl group may be attached to the rest of the molecule through any of the carbon atoms or the nitrogen atom (if present). In particular, the heterocyclic group may include, but is not limited to, a 4-membered ring such as azetidinyl, oxetanyl; a 5-membered ring such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or a 6-membered ring such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or a 7-membered ring such as diazepanyl. Optionally, the heterocyclic group may be benzo-fused. The heterocyclic group may be bicyclic, for example, but not limited to, a 5,5-membered ring such as hexahydrocyclopenta [c] pyrrole-2 (1H) -yl ring, or a 5,6-membered bicyclic ring such as hexahydropyrrolo [1,2-a] pyrazine-2 (1H) -yl ring. The ring containing the nitrogen atom may be partially unsaturated, i.e. it may contain one, two or more double bonds, such as but not limited to 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl, or it may be benzo-fused, such as but not limited to dihydroisoquinolinyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl. According to the present invention, the heterocyclic group is non-aromatic.
[0080] The term "C 6-20"Aryl" is understood to mean a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring having 6 to 20 carbon atoms, preferably "C 6-14 Aryl". The term "C 6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring ("C 6-14 or a ring having 9 carbon atoms ("C9 aryl"), for example indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 aryl) such as tetrahydronaphthyl, dihydronaphthyl or naphthyl, or a ring having 13 carbon atoms ("C 13 aryl), such as fluorenyl, or a ring having 14 carbon atoms ("C 14 aryl”), such as anthracenyl. When the C 6-20 When the aryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the position of substitution, and for example, substitution may be at the ortho, para or meta position.
[0081] The term "5-20 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5 to 20 ring atoms and containing 1 to 5 heteroatoms independently selected from N, O and S, for example "5-14 membered heteroaryl". The term "5-14 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and containing 1 to 5, preferably 1 to 3 heteroatoms each independently selected from N, O and S and, in addition, in each case may be benzo-fused. In particular, the heteroaryl group is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl and the like and benzo derivatives thereof, such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl and the like; or acininyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like. In addition, the heteroaryl group may also include a heteroaryl group formed by condensing two of the aforementioned heteroaryl groups, for example, a pyrazole-fused pyridyl group, in particular a pyrazolo[1,5-a]pyridyl group.
[0082] The above term “C 1-12 The definition of "alkyl" also applies to other C-containing 1-12 Alkyl groups, such as C 1-12 Alkoxy, etc.
[0083] Similarly, C 6-20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkyl has the same definition throughout. DETAILED DESCRIPTION
[0084] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.
[0085] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0086] Example 1: Preparation of (E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-[4-(trifluoromethyl)phenylsulfonyl]-4,5-dihydropyrazole-1-carboximide amide (Compound 1), (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 2), and (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 3)
[0087] Step 1: Synthesis of compound 5-chloro-N-methoxy-N-methylpyridine-2-carboxamide (2)
[0088] To a solution of 5-chloropyridine-2-carboxylic acid (5 g, 31.73 mmol, 1.00 equiv) in dichloromethane (50 mL) at room temperature were added 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (24.13 g, 63.47 mmol, 2.00 equiv), N,N-diisopropylethylamine (20.51 g, 158.68 mmol, 5.00 equiv), and methoxydimethylamine hydrochloride (3.58 g, 47.60 mmol, 1.5 equiv). After the addition was complete, the system was stirred at room temperature for 1 hour. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction solution was diluted with water (150 mL) and extracted with dichloromethane (3 × 80 mL). The organic phases were combined, backwashed with saturated brine (1 × 100 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 5-chloro-N-methoxy-N-methylpyridine-2-carboxamide (5.20 g, 81.67%) as a pale yellow oil. LCMS: (ESI, m / z): 201.00 [M+H] + .
[0089] Step 2: Synthesis of compound 1-(5-chloropyridin-2-yl)-2-propiophenone (3)
[0090] Under nitrogen, benzylmagnesium bromide (3.65 g, 18.69 mmol, 1.50 equiv) was added dropwise to a solution of 5-chloro-N-methoxy-N-methylpyridine-2-carboxamide (2.50 g, 12.46 mmol, 1.00 equiv) in tetrahydrofuran (25 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was quenched with ice water (20 mL) at 0°C, diluted with water (50 mL), and extracted with dichloromethane (3 × 60 mL). The combined organic phases were backwashed with saturated brine (1 × 80 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 1-(5-chloropyridin-2-yl)-2-propiophenylone (1.2 g, 41.56%) as a pale yellow oil. LCMS: (ESI, m / z): 232.05 [M+H] + Step 3: Synthesis of compound 1-(5-chloropyridin-2-yl)-2-phenylprop-2-en-1-one (4)
[0091] Under nitrogen, formaldehyde (388.8 mg, 12.95 mmol, 3.00 equiv), piperidine (735.04 mg, 8.63 mmol, 2.00 equiv), and glacial acetic acid (518.4 mg, 8.63 mmol, 2.00 equiv) were added to a solution of 1-(5-chloropyridin-2-yl)-2-propiophenone (1 g, 4.32 mmol, 1.00 equiv) in methanol (10 mL) at room temperature. The reaction mixture was heated to 60°C and stirred for 2 hours. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to remove methanol. The residue was diluted with water (50 mL) and extracted with ethyl acetate (3 × 40 mL). The organic phases were combined, backwashed with saturated brine (1 × 60 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure to afford 1-(5-chloropyridin-2-yl)-2-phenylprop-2-en-1-one (1 g, 95.06%) as a dark brown oil, which was used in the next step without further purification. LCMS: (ESI, m / z): 244.20 [M+H] + .
[0092] Step 4: Synthesis of compound 5-chloro-2-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine (5)
[0093] Under nitrogen, hydrazine hydrate (85%) (143.8 mg, 2.87 mmol, 0.70 equiv) was added to a solution of 1-(5-chloropyridin-2-yl)-2-phenylprop-2-en-1-one (1 g, 4.10 mmol, 1.00 equiv) in methanol (10 mL) at room temperature. The reaction mixture was heated to 60°C and stirred for 30 minutes. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with water (50 mL), and extracted with dichloromethane (2 × 50 mL). The organic phases were combined, backwashed with saturated brine (1 × 60 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. This afforded 5-chloro-2-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine (1 g, 94.16%) as a dark brown oil, which was used directly in the next step without further purification. LCMS: (ESI, m / z): 258.25 [M+H] + .
[0094] Step 5: Synthesis of compound (Z)-3-(5-chloropyridin-2-yl)-4-phenyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-thiocarbothioate (6)
[0095] Under nitrogen, triethylamine (1.17 g, 11.63 mmol, 3.00 equiv) and 1-chloro-1-(methylsulfonyl)-N-[4-(trifluoromethyl)phenylsulfonyl]methanimine (1.85 g, 5.82 mmol, 1.50 equiv) were added to a solution of 5-chloro-2-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine (1 g, 3.88 mmol, 1.00 equiv) in acetonitrile (10 mL) at room temperature. After the addition was complete, the system was stirred at 100°C for 2 hours. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with water (50 mL), and extracted with dichloromethane (3 × 40 mL). The organic phases were combined, backwashed with saturated brine (1 × 60 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give (Z)-methyl 3-(5-chloropyridin-2-yl)-4-phenyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carbothioate (1.2 g, 57.44%) as a yellow powder. LCMS: (ESI, m / z): 539.25 [M+H] + .
[0096] Step 6: Synthesis of compound (E)-N-[(1E)-1-aminoethylidene]-3-(5-chloropyridin-2-yl)-4-phenyl-N'-[4-(trifluoromethyl)phenylsulfonyl]-4,5-dihydropyrazole-1-carboximidamide (Compound 1)
[0097] Under nitrogen, triethylamine (112.65 mg, 1.11 mmol, 3.00 equiv) was added dropwise to a solution of (Z)-3-(5-chloropyridin-2-yl)-4-phenyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carbothioate (200 mg, 0.37 mmol, 1.00 equiv) in acetonitrile (2 mL) at room temperature. Acetamidine hydrochloride (52.62 mg, 0.56 mmol, 1.5 equiv) was added portionwise to the mixture at room temperature. After the addition was complete, the mixture was stirred at 100°C for 1 hour. The reaction mixture was cooled to room temperature, and distilled water (20 mL) was added to the reaction mixture. The mixture was extracted with ethyl acetate (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (1 × 20 mL), and dried over anhydrous sodium sulfate. The resulting filtrate was filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: XBridge Shield RP18OBD Column, 19*150 mm, 5 μm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 mL / min; elution gradient: 27% B to 70% B over 8 minutes, 70% B; detection wavelength: UV 254 nm / 220 nm. (E)-N-[(1E)-1-aminoethylidene]-3-(5-chloropyridin-2-yl)-4-phenyl-N'-[4-(trifluoromethyl)phenylsulfonyl]-4,5-dihydropyrazole-1-carboximidamide (88.8 mg, 43.29%) was obtained. 1 H NMR (400MHz, DMSO-d6) δ8.55-8.50(m,1H),8.01-7.92(m,3H),7.85(d,J=8.3Hz,3H),7.48(s,1H),7.32-7.24(m,3H),7.24-7.17(m,1 H),7.17-7.10(m,2H),5.06-4.98(m,1H),4.47(t,J=11.9Hz,1H),3.91(d,J=11.8Hz,1H),1.78(s,3H).LCMS:(ESI,m / z):549.10[M+H] + .
[0098] Step 7: Preparation of (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 2) and (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 3)
[0099] (E)-3-(5-Chloropyridin-2-yl)-4-phenyl-N'-[4-(trifluoromethyl)benzenesulfonyl]-4,5-dihydropyrazole-1-carboximide amide (50 mg) was separated by chiral preparative HPLC (Prep-Chiral HPLC) using the following conditions: Column chromatography specifications: CHIRALPAK IG, 2*25 cm, 5 μm; Mobile phase A: n-hexane (0.1% diethylamine)--HPLC, Mobile phase B: ethanol--HPLC; Flow rate: 20 mL / min; Elution solvent: 50% B, within 9 min; Detection wavelength: 254 nm / 220 nm; RT1 (min): 4.54; RT2 (min): 7.74; Sample solvent: methanol: dichloromethane = 1:1--HPLC; Single injection volume: 1.1 mL; Number of injections: 2. Separation gave compound (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 2) (10.4 mg, 41.6%), and gave compound (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 3) (12.3 mg, 49.2%).
[0100] Front peak: (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 2) 1H NMR(400MHz,DMSO-d6)δ8.53(s,1H),7.99-7.94(m,3H),7.87-7.81(m,3H),7.50(s,1H),7.29-7.26(m,3H),7.20-7.18(m,1H) ,7.15-7.11(m,2H),5.04-5.00(m,1H),4.50-4.43(m,1H),3.90(d,J=15.9Hz,1H),1.78(s,3H).LCMS:(ESI,m / z):548.85[M+H] + .
[0101] Later peak: (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 3) 1 H NMR(400MHz,DMSO-d6)δ8.52(s,1H),7.98-7.94(m,3H),7.86-7.83(m,3H),7.49(s,1H),7.29-7.23(m,3H),7.20-7.18(m,1H) ,7.15-7.11(m,2H),5.04-5.00(m,1H),4.50-4.44(m,1H),3.91(d,J=10.1Hz,1H),1.78(s,3H).LCMS:(ESI,m / z):548.85[M+H] + .
[0102] The compounds listed in Table 1 were prepared by referring to the method of Example 1. The structural characterization data of these compounds are listed in Table 1.
[0103] Table 1
[0104] Example 2: (E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 14), (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6 Preparation of (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 16)
[0105] Step 1-3: Synthesis of compound 5-chloro-2-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine (10)
[0106] Steps 1-3 were carried out in a similar manner to Steps 2-4 in Example 1 (with 5-chloropyridinyl cyanide as the starting material) to afford 5-chloro-2-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine (22 g, 94.16%) as a dark brown oil. The product was used directly in the next step without further purification. LCMS: (ESI, m / z): 258.07 [M+H] + .
[0107] Step 4: Synthesis of compound 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carbonyl chloride (11)
[0108] Under nitrogen, triethylamine (12.93 g, 128.04 mmol, 1.50 equiv) was added to a toluene solution (200 mL) of 5-chloro-2-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine (22 g, 85.36 mmol, 1.00 equiv) at room temperature. Triphosgene (20.31 g, 68.28 mmol, 0.80 equiv) was then added to the mixture under ice-cooling. After the addition was complete, the mixture was stirred at 100°C for 1 hour. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was cooled to room temperature, quenched by the addition of ice water (50 mL) at 0°C, and diluted with water (100 mL). The reaction mixture was extracted with dichloromethane (3 × 120 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (2 × 150 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carbonyl chloride (21 g, crude product) was obtained. It was directly used in the next step without further purification. LCMS: (ESI, m / z): 320.03 [M+H] + .
[0109] Step 5: Synthesis of compound 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carboxamide (12)
[0110] Under nitrogen, aqueous ammonia (40 mL) was added to a solution of 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carbonyl chloride (21 g, 65.62 mmol, 1.00 equiv) in 1,4-dioxane (40 mL) at room temperature. The reaction mixture was allowed to react at room temperature for 1 hour. After completion of the reaction by liquid chromatography-mass spectrometry, the reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (3 × 200 mL). The combined organic phases were backwashed with saturated sodium chloride solution (2 × 200 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carboxamide (6.6 g, 33.41%). LCMS: (ESI, m / z): 301.08 [M+H] + .
[0111] Step 6: Synthesis of compound 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carbonitrile (13)
[0112] Under nitrogen, triphenylphosphine oxide (24.97 mg, 0.093 mmol, 0.01 equiv) and TEA (2.72 g, 26.93 mmol, 3.00 equiv) were added to a solution of 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carboxamide (2.7 g, 8.98 mmol, 1.00 equiv) in dichloromethane (25 mL) at room temperature. Oxalyl chloride (2.28 g, 17.95 mmol, 2.00 equiv) was added dropwise at 0°C over approximately 20 minutes. After the addition was complete, the system was stirred at room temperature for 1 hour. The reaction was quenched by liquid chromatography-mass spectrometry (LC-MS / MS) at 0°C with water (30 mL), diluted with water (60 mL), and the reaction mixture was extracted with dichloromethane (3 x 60 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (2 × 60 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carbonitrile (1.5 g, 59.09%). LCMS: (ESI, m / z): 283.07 [M+H] + .
[0113] Step 7: Synthesis of compound (E)-N-(1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide (14)
[0114] Under nitrogen, KCO (2.2 g, 15.9 mmol, 3.00 equiv) and acetamidine hydrochloride (1.0 g, 10.6 mmol, 2.00 equiv) were added to a solution of 3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydropyrazole-1-carbonitrile (1.5 g, 5.3 mmol, 1.00 equiv) in N,N-dimethylformamide (15 mL) at room temperature. After the addition was complete, the system was stirred at room temperature for 3 hours. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The organic phases were combined, backwashed with water (3 × 60 mL), saturated brine (3 × 60 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure to give (E)-N-(1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide (1.8 g, crude product), which was directly used in the next step without further purification. LCMS: (ESI, m / z): 341.12 [M+H] + .
[0115] Step 8: Synthesis of compound (E)-3-(5-chloropyridin-2-yl)-N-acetimido-4-phenyl-N'-[6-(trifluoromethyl)pyridin-3-ylsulfonyl]-4,5-dihydropyrazole-1-carboximidamide (Compound 14)
[0116] Under nitrogen, triethylamine (772.79 mg, 7.65 mmol, 2.00 equiv) was added to a solution of 3-(5-chloropyridin-2-yl)-N-acetimido-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (1.3 g, 3.83 mmol, 1.00 equiv) in dichloromethane (13 mL) at room temperature. 6-(Trifluoromethyl)pyridine-3-sulfonyl chloride (1.4 g, 5.72 mmol, 1.50 equiv) was added to the above mixture at 0°C. After the addition was complete, the mixture was returned to room temperature and stirred for 30 minutes. Liquid chromatography-mass spectrometry indicated that the reaction was complete. The reaction mixture was quenched with water (20 mL) and diluted with water (60 mL). The reaction mixture was extracted with dichloromethane (3 × 60 mL). The combined organic phases were backwashed with saturated sodium chloride (2 × 60 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: XBridge Shield RP18 OBD Column, 30*150 mm, 5 μm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 mL / min; elution solvent: 10% to 70% B; detection wavelength: UV 254 nm / 220 nm. (E)-3-(5-chloropyridin-2-yl)-N-acetimido-4-phenyl-N'-[6-(trifluoromethyl)pyridin-3-ylsulfonyl]-4,5-dihydropyrazole-1-carboximidamide (Compound 14) (630 mg, 30.04%) was obtained. 1 H NMR(400MHz, DMSO-d6)δ9.06(d,J=2.1Hz,1H),8.56-8.51(m,1H),8.43-8.36(m,1H),8.07-8.01(m,1H),8.00-7.92(m,1H),7.82(d,J=8.6Hz,1H) ,7.61(s,1H),7.40(s,1H),7.32-7.24(m,2H),7.23-7.10(m,3H),5.08-4 .99(m,1H),4.50(t,J=11.8Hz,1H),3.93(d,J=10.4Hz,1H),1.83(s,3H). LCMS:(ESI,m / z):549.85[M+H] + .
[0117] Step 9: Synthesis of compounds (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 15) and (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 16)
[0118] (E)-N-((E)-1-Aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 14) (100 mg) was separated by chiral preparative HPLC using the following conditions: Column chromatography specifications: CHIRALPAK ID, 2*25 cm, 5 μm; Mobile phase A: n-hexane (0.1% DEA)--HPLC, Mobile phase B: ethanol--HPLC; Flow rate: 20 mL / min; Elution solvent: 20% B within 14 min; Detection wavelength: 254 / 220 nm; RT1 (min): 10.88; RT2 (min): 12.61; Sample solvent: methanol: dichloromethane = 3:1--HPLC; Single injection volume: 0.4 mL; Number of injections: 53. The compound (R, E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 15) (39.2 mg, 78.4%) was obtained, and the compound (S, E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 16) (42.4 mg, 84.4%) was obtained.
[0119] Front peak: (R,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 15)
[0120] 1H NMR(400MHz,DMSO-d6)δ9.06(s,1H),8.53(d,J=1.8Hz,1H),8.39(d,J=8.7Hz,1 H),8.04(d,J=8.2Hz,1H),7.97-7.95(m,1H),7.82(d,J=8.5Hz,1H),7.61(s,1H) ,7.39(s,1H),7.29-7.26(m,2H),7.22-7.13(m,3H),5.05-5.03(m,1H),4.56-4 .44(m,1H),3.92(d,J=17.4Hz,1H),1.83(s,3H).LCMS:(ESI,m / z):549.80[M+H] + .
[0121] Later peak: (S,E)-N-((E)-1-aminoethylidene)-3-(5-chloropyridin-2-yl)-4-phenyl-N'-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 16) 1 H NMR(400MHz,DMSO-d6)δ9.07(s,1H),8.53(d,J=2.3Hz,1H),8.40(d,J=9.6Hz,1 H),8.04(d,J=8.2Hz,1H),7.97-7.95(m,1H),7.82(d,J=8.4Hz,1H),7.62(s,1H) ,7.40(s,1H),7.40-7.26(m,2H),7.22-7.14(m,3H),5.05-5.03(m,1H),4.54-4 .48(m,1H),3.93(d,J=11.3Hz,1H),1.84(s,3H).LCMS:(ESI,m / z):549.85[M+H] + .
[0122] The compounds shown in Table 2 were prepared by referring to the method of Example 2. The structural characterization data of these compounds are listed in Table 2.
[0123] Table 2
[0124] Example 3: (E)-N-((E)-1-aminoethylidene)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 36), (R,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide Preparation of -(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 37) and (S,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 38)
[0125] Step 1-4: Synthesis of compound 5-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-(trifluoromethyl)pyridine (19)
[0126] The first four steps were performed using a method similar to Example 1 (with 6-(trifluoromethyl)nicotinic acid as the starting material) to obtain 5-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-(trifluoromethyl)pyridine (2 g, 95.19%), which was used directly in the next step without further purification. LCMS: (ESI, m / z): 292.00 [M+H] + .
[0127] Step 5: Synthesis of compound 4-phenyl-N-[4-(trifluoromethyl)benzenesulfonyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydropyrazole-1-carboxamide (20)
[0128] Under nitrogen, methyl N-[4-(trifluoromethyl)phenylsulfonyl]carbamate (641.74 mg, 2.27 mmol, 1.20 equiv) was added to a toluene solution (6 mL) of 5-(4-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2-(trifluoromethyl)pyridine (550 mg, 1.89 mmol, 1 equiv) at room temperature. The reaction mixture was heated to 100°C and stirred for 2 hours. The reaction was complete as determined by liquid chromatography-mass spectrometry. The reaction mixture was cooled to room temperature, and the resulting residue was concentrated under reduced pressure. The resulting residue was diluted with water (40 mL) and extracted with ethyl acetate (3 × 40 mL). The combined organic phases were backwashed with saturated sodium chloride solution (1 × 60 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography to give 4-phenyl-N-[4-(trifluoromethyl)benzenesulfonyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydropyrazole-1-carboxamide (350 mg, 34.17%). LCMS: (ESI, m / z): 543.20 [M+H] + .
[0129] Step 6: Synthesis of compound (Z)-4-phenyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidoyl chloride (21)
[0130] Under nitrogen, phosphorus pentachloride (552.74 mg, 2.66 mmol, 8.00 equiv) was added to a solution of 4-phenyl-N-[4-(trifluoromethyl)phenylsulfonyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydropyrazole-1-carboxamide (180 mg, 0.33 mmol, 1.00 equiv) in chlorobenzene (4 mL) at room temperature. The reaction mixture was heated to 100°C and stirred for 15 minutes. After the reaction was complete, the reaction mixture was cooled to room temperature and quenched with ice water (10 mL). The mixture was diluted with water (20 mL) and extracted with dichloromethane (3 × 30 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1 × 30 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure to afford (Z)-4-phenyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidoyl chloride (180 mg, crude) as a pale yellow oil. The product was used directly in the next step without further purification. LCMS: (ESI, m / z): 561.15 [M+H] + .
[0131] Step 7: Synthesis of compound (E)-N-((E)-1-aminoethylidene)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 36)
[0132] Under nitrogen, a solution of acetamidine hydrochloride (82.79 mg, 0.64 mmol, 2.00 equiv) and N,N-diisopropylethylamine (207.39 mg, 1.61 mmol, 5.00 equiv) in isopropanol (1 mL) was stirred at room temperature for 30 minutes. (Z)-4-phenyl-N-[4-(trifluoromethyl)phenylsulfonyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydropyrazole-1-carbonylaminocarboxamide chloride (180 mg, 0.32 mmol, 1.00 equiv) in dichloromethane (2 mL) was added dropwise at 0°C. After the addition was complete, the reaction mixture was stirred at room temperature overnight. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The mixture was diluted with water (20 mL) and extracted with dichloromethane (3 × 20 mL). The combined organic phases were backwashed with saturated sodium chloride (1 × 30 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: column specifications: Xselect CSH C18 OBD Column 30*150mm 5μm, n; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; flow rate: 60mL / min; elution solvent: 30%B to 70%B; detection wavelength: UV 254nm / 220nm; retention time (min): 7.87. Purification afforded (E)-N-[(1E)-1-aminoethylidene]-4-phenyl-N'-[4-(trifluoromethyl)benzenesulfonyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydropyrazole-1-carboximidamide (Compound 36) (49.2 mg, 26.19%). 1 H NMR (400MHz, DMSO-d6) δ8.85(s,1H),8.19(d,J=8.4Hz,1H),8.02(d,J=8.2Hz,2H),7.94-7.84(m,3H),7.37(t,J=7.4Hz,2H),7.30(t,J=7.2 Hz,1H),7.26-7.20(m,2H),5.19-5.10(m,1H),4.56(t,J=11.8Hz,1H),3.96(d,J=10.1Hz,1H),1.82(s,3H).LCMS:(ESI,m / z):583.10[M+H] + .
[0133] Step 8: Synthesis of (R,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 37) and (S,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 38)
[0134] (E)-N-[(1E)-1-Aminoethylidene]-4-phenyl-N'-[4-(trifluoromethyl)benzenesulfonyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydropyrazole-1-carboximidamide (Compound 36) (15.6 mg) was separated by chiral preparative HPLC using the following conditions: chromatographic column specifications: (R,R)-WHELK-01-Kromasil, 5*25 cm, 5 μm; mobile phase A: Hex (0.1% DEA)--HPLC, mobile phase B: EtOH--HPLC; flow rate: 20 mL / min; elution solvent: 20% B within 16 min; detection wavelength: UV 254 nm / 220 nm; retention time (minutes): 12.73; RT2 (min): 14.7; sample solvent: MeOH--HPLC; single injection volume: 0.3 mL; number of injections: 5. Separation gave compound (R,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 37) (7.2 mg, 92.31%), and compound (S,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximide amide (Compound 38) (2.5 mg, 32.05%).
[0135] Front peak: (R,E)-N-(1-Iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 37)
[0136] 1H NMR (400 MHz, deuterated chloroform) δ 8.90 (s, 1H), 8.07 (d, J = 8.1 Hz, 3H), 7.72 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.38-7.29 (m, 3H), 7.13 (d, J = 7.1 Hz, 2H), 5.79 (s, 1H), 4.94-4.69 (m, 1H), 4.63 (t, J = 12.0 Hz, 1H), 4.35-4.03 (m, 1H), 2.16 (s, 3H), 1.46 (t, J = 7.2 Hz, 1H). LCMS: (ESI, m / z): 582.80 [M+H] + .
[0137] Later peak: (S,E)-N-(1-iminoethyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 38)
[0138] 1 H NMR (400 MHz, deuterated chloroform) δ 8.90 (s, 1H), 8.16-7.94 (m, 3H), 7.72 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.39-7.27 (m, 3H), 7.13 (d, J = 7.0 Hz, 2H), 6.07 (s, 1H), 4.85-4.74 (m, 1H), 4.65 (t, J = 12.0 Hz, 1H), 4.24-4.14 (m, 1H), 2.18 (s, 3H), 1.45 (t, J = 7.3 Hz, 1H). LCMS: (ESI, m / z): 582.80 [M+H] + .
[0139] The compounds shown in Table 3 were prepared by referring to the method of Example 3. The structural characterization data of these compounds are listed in Table 3.
[0140] Table 3
[0141] Example 4: Preparation of (E)-N-((E)-1-aminoethylidene)-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 41)
[0142] Step 1: Synthesis of compound 1-(2,3-dihydro-1H-inden-5-yl)-2-propiophenone (23)
[0143] Under nitrogen, aluminum trichloride (8.46 g, 63.46 mmol, 0.50 equiv) was added to a solution of 2,3-dihydro-1H-indene (15 g, 126.92 mmol, 1.00 equiv) in dichloromethane (150 mL) at room temperature. Phenylacetyl chloride (9.81 g, 63.46 mmol, 0.50 equiv) was then slowly added dropwise to the solution under an ice bath, maintaining the temperature at 0°C. After the addition was complete, the reaction system was allowed to continue at 0°C for 1 hour. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was quenched by the addition of ice water (200 mL) at 0°C and extracted with dichloromethane (3 × 100 mL). The organic phases were combined, backwashed with saturated brine (1 × 100 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 1-(2,3-dihydro-1H-inden-5-yl)-2-propiophenone (7 g, 23.34%). LCMS: (ESI, m / z): 237.00 [M+H] + .
[0144] Step 2: Synthesis of compound 1-(2,3-dihydro-1H-inden-5-yl)-2-phenylprop-2-en-1-one (24)
[0145] To a solution of 1-(2,3-dihydro-1H-inden-5-yl)-2-propiophenone (1 g, 4.23 mmol, 1.00 equiv) in methanol (10 mL) were added acetic acid (508.24 mg, 8.46 mmol, 2.00 equiv), formaldehyde (1030.21 mg, 12.70 mmol, 3.00 equiv, 37%), and piperidine (720.63 mg, 8.46 mmol, 2.00 equiv) at room temperature. Under nitrogen, the reaction mixture was incubated at 60°C for 3 hours. The reaction was complete after liquid chromatography-mass spectrometry. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with distilled water (80 mL) and extracted with ethyl acetate (2 × 60 mL). The organic phases were combined, backwashed with saturated brine (1 × 50 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure to give 1-(2,3-dihydro-1H-inden-5-yl)-2-phenylprop-2-en-1-one (1 g, 85.65%), which was used directly in the next reaction without purification. LCMS: (ESI, m / z): 249.05 [M+H] + .
[0146] Step 3: Synthesis of compound 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazole (25)
[0147] Under nitrogen, hydrazine hydrate (141.12 mg, 2.82 mmol, 0.70 equiv) was added to a solution of 1-(2,3-dihydro-1H-inden-5-yl)-2-phenylpropanone-1-ene (1 g, 4.03 mmol, 1.00 equiv) in methanol (10 mL) at room temperature. The mixture was allowed to react at 80°C for 16 hours. The reaction was complete as determined by liquid chromatography-mass spectrometry. After concentration under reduced pressure, the resulting residue was dissolved in ethyl acetate (80 mL), washed with distilled water (2 × 60 mL), and backwashed with saturated brine (1 × 50 mL). The organic phase was dried over anhydrous sodium sulfate, the resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazole (580 mg, 54.90%). LCMS: (ESI, m / z): 263.05 [M+H] + .
[0148] Step 4: Synthesis of compound 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (26)
[0149] Under nitrogen, S-methylisothiourea sulfate (298.91 mg, 3.32 mmol, 1.50 equiv) was added to a solution of 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazole (580 mg, 2.21 mmol, 1.00 equiv) in pyridine (6 mL) at room temperature. The reaction mixture was incubated at 100°C for 48 hours, monitored by liquid chromatography-mass spectrometry. The reaction mixture was cooled to room temperature, and methyl tert-butyl ether (50 mL) was added to the system. The mixture was stirred at room temperature for 30 minutes, filtered, and the filter cake was collected and washed with methyl tert-butyl ether (3×10 mL). The solid was dissolved in methanol (10 mL), and 5 mol / L sodium hydroxide solution (5 mL) was added, followed by distilled water (30 mL). The mixture was stirred at room temperature for 20 minutes, filtered, and the filter cake was collected and washed with water (5×10 mL). The resulting solid was dried to give 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (120 mg, 17.83%). LCMS: (ESI, m / z): 305.10 [M+H] + .
[0150] Step 5: Synthesis of N-[(1E)-1-aminoethylidene]-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (27)
[0151] To a solution of ethyl acetimidate hydrochloride (389.74 mg, 3.15 mmol, 8.00 equiv) in water (2 mL) was added potassium carbonate (2.3 mL, 13.33 mmol, 33.82 equiv, 3 mol / L) at room temperature. The reaction mixture was stirred at room temperature for 20 minutes, followed by the addition of dichloromethane (6 mL) and continued stirring for 10 minutes. The organic phase was separated, dried over anhydrous sodium sulfate, and filtered. To the filtrate was then added 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (120 mg, 0.394 mmol, 1.00 equiv). The reaction was allowed to proceed at 50°C for 2 days. Liquid chromatography-mass spectrometry (LC-MS / MS) was used to monitor the reaction, indicating that 25% of the starting material remained. The reaction mixture was cooled to room temperature, diluted with dichloromethane (30 mL), washed with distilled water (3 × 20 mL), and washed with saturated brine (1 × 30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain N-[(1E)-1-aminoethylidene]-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (130 mg, crude product). LCMS: (ESI, m / z): 346.15 [M+H] + .
[0152] Step 6: Synthesis of (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-acetimido-4-phenyl-N'-[4-(trifluoromethyl)phenylsulfonyl]-4,5-dihydropyrazole-1-carboximidamide (Compound 41)
[0153] To a solution of N-[(1E)-1-aminoethylidene]-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydropyrazole-1-carboximidamide (120 mg, 0.347 mmol, 1.00 equiv) in dichloromethane (3 mL) at room temperature was added triethylamine (105.46 mg, 1.041 mmol, 3.00 equiv), followed by the addition of 4-(trifluoromethyl)benzenesulfonyl chloride (127.46 mg, 0.520 mmol, 1.50 equiv) at 0°C. The reaction system was warmed to room temperature and stirred for 30 minutes. The reaction was complete after liquid chromatography-mass spectrometry. The reaction system was quenched with distilled water (10 mL) at 0°C and extracted with dichloromethane (3 × 20 mL). The organic phases were combined, backwashed with saturated brine (1 × 30 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative HPLC using the following conditions: column specifications: Xselect CSH C18 OBD Column 30*150mm 5μm, n; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 mL / min; elution solvent: 40% B to 67% B; detection wavelength: UV 254 nm / 220 nm; retention time (min): 8.67. (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-acetimido-4-phenyl-N'-[4-(trifluoromethyl)phenylsulfonyl]-4,5-dihydropyrazole-1-carboximidamide (56.0 mg, 29.11%) was obtained. 1 H NMR (400 MHz, deuterated methanol) δ 7.95 (d, J = 8.1 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.38 (s, 1H), 7.27 (d, J = 7.9 Hz, 1H), 7.19 (t, J = 7.4 Hz, 2H), 7.13 (t, J = 7.2 Hz, 1H), 7.09-7.03 (m, 2H), 6. 99(d,J=7.9Hz,1H),4.89-4.80(m,1H),4.38(t,J=11.8Hz,1H),3.89(d,J=11.0Hz,1 H),2.83-2.54(m,4H),1.97-1.84(m,2H),1.75(s,3H).LCMS(ESI,m / z):554.05[M+H] + .
[0154] The compounds shown in Table 4 were prepared by referring to the method of Example 4. The structural characterization data of these compounds are listed in Table 4.
[0155] Table 4
[0156] Example 5: Preparation of (E)-N-(N-((3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)aminoamido)acetamide (Compound 46) and (E)-N-carbamoyl-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 47)
[0157] A similar method to Example 3 was used (the starting material was replaced with 3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazole (25)) to obtain (E)-N-(N-((3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)aminoamido)acetamide (Compound 46) (2.0 mg, 5.89%), and (E)-N-carbamoyl-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 47) (2.3 mg, 4.21%).
[0158] (E)-N-(N-((3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)aminoamido)acetamide (Compound 46): 1 H NMR (400MHz, DMSO-d6) δ10.50(s,1H),8.00(d,J=7.9Hz,2H),7.82(d,J=8.4 Hz,2H),7.72-7.61(m,1H),7.59-7.45(m,1H),7.43-7.06(m,6H),7.04-6.89 (m,1H),5.04-4.96(m,1H),4.44(t,J=11.6Hz,1H),3.87-3.82(m,1H),2.87 -2.62(m,4H),2.08(s,3H),2.00-1.89(m,2H).LCMS(ESI,m / z):597.00[M+H] + .
[0159] (E)-N-Carbamoyl-3-(2,3-dihydro-1H-inden-5-yl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide (Compound 47) (2.3 mg, 4.21%): 1 H NMR(400MHz, DMSO-d6)δ8.00(t,J=7.4Hz,2H),7.87-7.75(m,2H),7.34-7.11(m,6H),7.10-6.93(m,2H),6.78-6.54(m,4H),4.8 7-4.79(m,1H),4.36(t,J=11.6Hz,1H),3.89-3.79(m,1H),2.81-2.64(m,4H),1.98-1.90(m,2H).LCMS(ESI,m / z):555.00[M+H] + .
[0160] The compounds shown in Table 5 were prepared by referring to the methods of Examples 4 and 5. The structural characterization data of these compounds are listed in Table 5.
[0161] Table 5
[0162] Example 6: Preparation of (Z)-N-((E)-1-aminoethylidene)-7-chloro-1-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-1,2-dihydro-3H-benzo[e]indole-3-carboximidamide (Compound 50)
[0163] Step 1: Synthesis of compound 1-(4-toluenesulfonyl)-2-phenylaniline (31)
[0164] To a solution of 2-amino-2-phenylethanol (2 g, 14.58 mmol, 1.00 equiv) and triethylamine (7.38 g, 72.90 mmol, 5.00 equiv) in dichloromethane (35 mL) at 0°C was added p-toluenesulfonyl chloride (8.34 g, 43.74 mmol, 3.00 equiv). The reaction mixture was warmed to room temperature and allowed to react for 16 hours. The reaction was complete after HPLC-MS analysis. The reaction mixture was diluted with water (80 mL) and extracted with dichloromethane (3 × 60 mL). The combined organic phases were backwashed with saturated brine (1 × 50 mL) and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 1-(4-tosyl)-2-phenylaniline (2 g, 50.19%). LCMS: (ESI, m / z): 274.00 [M+H] + .
[0165] Step 2: Synthesis of compound 7-chloro-3-(4-methylphenylsulfonyl)-1-phenyl-1H,2H-benz[e]indole (32)
[0166] To a solution of 1-(4-tosyl)-2-phenylaniline (1 g, 3.66 mmol, 1.00 equiv) and 2-chloro-6-hydroxynaphthalene (784.14 mg, 4.39 mmol, 1.20 equiv) in 1,2-dichloroethane (20 mL) under nitrogen was added silver trifluoromethanesulfonate (93.99 mg, 0.37 mmol, 0.10 equiv) at room temperature. The reaction mixture was heated to 80°C and allowed to react for 12 hours. The reaction was complete by liquid chromatography-mass spectrometry. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with dichloromethane (3 × 10 mL). The filtrate was diluted with dichloromethane (80 mL), washed with water (3 × 80 mL), and then with saturated brine (1 × 50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 7-chloro-3-(4-methylphenylsulfonyl)-1-phenyl-1H,2H-benz[e]indole (1.7 g, 107.08%). LCMS: (ESI, m / z): 433.95 [M+H] + .
[0167] Step 3: Synthesis of compound 7-chloro-1-phenyl-1H,2H,3H-benz[e]indole (33)
[0168] Under nitrogen, magnesium turnings (1.12 g, 46.08 mmol, 20.00 equiv) were added to a solution of 7-chloro-3-(4-methylphenylsulfonyl)-1-phenyl-1H,2H-benz[e]indole (1 g, 2.30 mmol, 1.00 equiv) in methanol (10 mL) at room temperature. The reaction mixture was heated to 60°C and allowed to react for 16 hours, monitored by liquid chromatography-mass spectrometry. The reaction mixture was cooled to room temperature and quenched with saturated ammonium chloride solution (20 mL). The mixture was filtered and the filter cake was washed with dichloromethane (3 × 10 mL). The filtrate was diluted with dichloromethane (100 mL) and washed with water (3 × 60 mL) and saturated brine (1 × 50 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography to give 7-chloro-1-phenyl-1H,2H,3H-benz[e]indole (410 mg, 63.59%). LCMS: (ESI, m / z): 280.00 [M+H]. + .
[0169] The remaining steps were carried out in a similar manner to Example 1 (the starting material was replaced with 7-chloro-1-phenyl-1H,2H,3H-benz[e]indole) to obtain compound (Z)-N-((E)-1-aminoethylidene)-7-chloro-1-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-1,2-dihydro-3H-benz[e]indole-3-carboximidamide (Compound 50) (63.6 mg, 15.57%). 1 H NMR (400MHz, CDCl3) δ8.07(d,J=7.8Hz,2H),7.83-7.63(m,4H),7.40-7.25(m,2H),7.25-7.13(m,4H),7.05(d,J=7.0Hz,2 H),5.27(s,2H),4.91-4.83(m,1H),4.62-4.45(m,1H),4.01(d,J=74.3Hz,1H),2.11(s,3H).LCMS(ESI,m / z):571.00[M+H] + .
[0170] The compounds shown in Table 6 were prepared by referring to the method of Example 6. The structural characterization data of these compounds are listed in Table 6.
[0171] Table 6
[0172] Example 7: Preparation of (E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboximide amide (Compound 61), Compound (S,E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboxamide (Compound 62) and (R,E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboximide amide (Compound 63)
[0173] Step 1: Synthesis of compound 4-(4-chlorophenyl)-4-oxo-3-phenylbutyric acid methyl ester (36)
[0174] Under nitrogen, sodium hydride (0.78 g, 32.51 mmol, 1.50 equiv) was added to a solution of 1-(4-chlorophenyl)-2-propiophenone (5 g, 21.67 mmol, 1.00 equiv) in dimethyl sulfoxide (50 mL) at 0°C. Stirring was continued for 1 hour, and then methyl 2-bromoacetate (3.1 mL, 20.27 mmol, 0.93 equiv) was slowly added dropwise. After the addition was complete, the reaction solution was warmed to room temperature and the reaction continued for 1 hour. The reaction system was monitored by liquid chromatography-mass spectrometry. After completion of the reaction, the solution was quenched with water (100 mL) in an ice bath. The aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organic phases were backwashed with saturated brine (1 × 100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give methyl 4-(4-chlorophenyl)-4-oxo-3-phenylbutyrate (3.5 g, 53.34%). LCMS: (ESI, m / z): 303.00 [M+H] + .
[0175] Step 2: Synthesis of compound 4-(4-chlorophenyl)-4-oxo-3-phenylbutyric acid (37)
[0176] Under nitrogen, sodium hydroxide (924.79 mg, w:w = 25%, 2 eq) was added to a solution of methyl 4-(4-chlorophenyl)-4-oxo-3-phenylbutyrate (3.5 g, 11.561 mmol, 1.00 eq) in ethanol (15 mL) and water (15 mL) at room temperature. The reaction was stirred at room temperature for 16 hours. The reaction was monitored by liquid chromatography-mass spectrometry. After completion, the reaction system was acidified to pH 5 with hydrochloric acid and diluted with water (100 mL). The aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organic phases were backwashed with saturated brine (1 × 100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield 4-(4-chlorophenyl)-4-oxo-3-phenylbutyric acid (3 g, 89.82%). The product was used directly in the next step without further purification. LCMS: (ESI, m / z): 289.00 [M+H] + .
[0177] Step 3: Synthesis of compound 6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one (38)
[0178] Under nitrogen, hydrazine hydrate (333.30 μL, 6.86 mmol, 1.98 equiv) was added to a solution of 4-(4-chlorophenyl)-4-oxo-3-phenylbutyric acid (1 g, 3.46 mmol, 1.00 equiv) in ethanol (10 mL) at room temperature. The reaction mixture was warmed to 70°C and stirred for 16 hours. The desired product was found in the liquid phase. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to yield 6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one (600 mg, 60.84%). LCMS: (ESI, m / z): 285.05 [M+H] + .
[0179] Step 4: Synthesis of compound 3-(4-chlorophenyl)-4-phenyl-1,4,5,6-tetrahydropyridazine (39)
[0180] Under nitrogen, lithium aluminum hydride (159.94 mg, 4.21 mmol, 2.00 equiv) was added dropwise to a solution of 6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one (600 mg, 2.11 mmol, 1.00 equiv) in tetrahydrofuran (6 mL) at -40°C. The reaction mixture was then warmed to 60°C and stirred for 30 minutes. The desired product was found in the liquid phase. The reaction mixture was cooled to room temperature, quenched with ice water (40 mL) in an ice bath, and extracted with ethyl acetate (2 x 40 mL). The organic phases were combined, backwashed with saturated brine (1 x 30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to yield 3-(4-chlorophenyl)-4-phenyl-1,4,5,6-tetrahydropyridazine (300 mg, 52.58%). LCMS: (ESI, m / z): 271.05 [M+H] + .
[0181] Step 5: Synthesis of compound (Z)-3-(4-chlorophenyl)-4-phenyl-N-((4-(trifluoromethyl)phenyl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carbothioate (40)
[0182] Under nitrogen protection, 1-chloro-1-(methylsulfonyl)-N-[4-(trifluoromethyl)phenylsulfonyl]methanimine (190.10 mg, 0.60 mmol, 1.20 equiv) and triethylamine (207.92 uL, 1.50 mmol, 3.00 equiv) were added to a solution of 3-(4-chlorophenyl)-4-phenyl-1,4,5,6-tetrahydropyridazine (135 mg, 0.50 mmol, 1.00 equiv) in acetonitrile (4 mL) at room temperature. The reaction solution was heated to 100°C and stirred for 2 hours. The reaction was complete as monitored by liquid chromatography-mass spectrometry. The reaction solution was cooled to room temperature and the resulting mixture was used directly in the next reaction without further treatment. LCMS: (ESI, m / z): 552.05 [M+H] + .
[0183] Step 6: Synthesis of (E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboximidamide (Compound 61)
[0184] Under nitrogen, a solution of acetamide hydrochloride (6.85 mg, 0.072 mmol, 2.00 equiv) and triethylamine (15.11 uL, 0.11 mmol, 3.00 equiv) in acetonitrile (0.50 mL) was added to the reaction solution from the previous step at room temperature. The reaction solution was heated to 100°C and stirred for 2 hours. The desired product was detected in the liquid. The reaction solution was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (2 × 40 mL). The organic phases were combined, backwashed with saturated brine (1 × 50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: column dimensions: XBridge Prep BEH130 C18 Column, 19 x 100 mm, 5 μm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 mL / min; elution solvent: 25% B to 75% B; detection wavelength: UV 220 nm; retention time (min): 6.85. Purification afforded (E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboximidamide (Compound 61) (99.2 mg, 72.18%). 1H NMR (400MHz, DMSO-d6) δ8.01-7.96 (m, 2H), 7.86 (d, J = 8.3Hz, 2H), 7.62-7. 56(m,2H),7.53(s,1H),7.36-7.27(m,5H),7.25-7.19(m,1H),7.16-7.10(m ,2H),4.45-4.39(m,1H),4.32(d,J=13.3Hz,1H),3.18-3.06(m,1H),2.27- 2.15(m,1H),2.05-1.92(m,1H),1.74(s,3H).LCMS(ESI,m / z):561.90[M+H] + 。
[0185] Step 7: Synthesis of Compound 62 and Compound 63
[0186] Compound 61 (82 mg) was resolved by chiral preparative HPLC using the following conditions: column size: CHIRALPAK IC, 2 x 25 cm, 5 μm; mobile phase A: n-hexane (0.1% diethylamine) - HPLC, mobile phase B: ethanol - HPLC; flow rate: 20 mL / min; elution solvent: 30% B over 25 min; detection wavelength: UV 220 nm / 254 nm; retention time of the front peak (min): 8.76; retention time of the rear peak (min): 19.85; solvent: methanol - HPLC; single injection volume: 1.2 mL; number of injections: 2. Compound 62 (29.3 mg, 71.46%) and compound 63 (27.6 mg, 67.32%) were obtained.
[0187] Front peak: (Compound 62) 1 H NMR (400MHz, DMSO-d6) δ7.99(d,J=8.2Hz,2H),7.87(d,J=8.3Hz,2H),7.59( d,J=8.6Hz,2H),7.53(s,1H),7.34-7.28(m,5H),7.24-7.20(m,1H),7.14(d, J=7.3Hz,2H),4.42(s,1H),4.33(d,J=13.0Hz,1H),3.17-3.09(m,1H),2.27 -2.15(m,1H),2.02-1.93(m,1H),1.75(s,3H).LCMS(ESI,m / z):561.85[M+H] + .
[0188] Later peak: (Compound 63) 1H NMR (400MHz, DMSO-d6) δ7.99(d,J=8.2Hz,2H),7.87(d,J=8.4Hz,2H),7.59(d,J=8.6Hz,2H),7.53(s,1H),7.34-7.28(m,5H),7.24-7.20(m,1H LCMS (ES,m / z):561.80[M+H] + .
[0189] The compounds shown in Table 7 were prepared by referring to the method of Example 7. The structural characterization data of these compounds are listed in Table 7.
[0190] Table 7
[0191] Example 8: Preparation of N-((E)-N'-((E)-(3-(4-chlorophenyl)-4-phenyl-5,6-dihydropyridazin-1(4H)-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)aminoamido)acetamide (Compound 67)
[0192] A similar method to Example 3 was used (the starting material was replaced with 3-(4-chlorophenyl)-4-phenyl-1,4,5,6-tetrahydropyridazine (39)) to obtain compound N-((E)-N'-((E)-(3-(4-chlorophenyl)-4-phenyl-5,6-dihydropyridazin-1(4H)-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)aminoamido)acetamide (Compound 67) (16.7 mg, 9.87%). 1 H NMR (400MHz, DMSO-d6) δ10.68(d,J=7.9Hz,1H),8.17(d,J=25.0Hz,1H),8.04(d,J=8 .1Hz,2H),7.85(d,J=8.1Hz,3H),7.53(d,J=8.4Hz,2H),7.34-7.23(m,4H),7.21(d, J=7.4Hz,1H),7.19-7.04(m,2H),4.62-4.21(m,2H),3.27-3.04(m,1H),2.21(d,J=1 3.3Hz,1H),2.10(d,J=7.3Hz,3H),2.03-1.91(m,1H).LCMS(ESI,m / z):604.80[M+H]+ .
[0193] Example 9: Preparation of (E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboximidamide (Compound 68)
[0194] A similar method to Example 2 was used (the starting material was replaced by 3-(4-chlorophenyl)-4-phenyl-1,4,5,6-tetrahydropyridazine (44)) to obtain compound (E)-N-((E)-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)sulfonyl)-5,6-dihydropyridazine-1(4H)-carboximide amide (Compound 68) (20.7 mg, 13.27%). 1 H NMR (400MHz, DMSO-d6) δ7.64(d,J=8.7Hz,2H),7.50-7.29(m,6H),7.23(t,J=7.4Hz,1H),7.18-7.13(m,2H),4.44(d,J=4.7Hz,1H),4.29( d,J=13.2Hz,1H),3.13-3.07(m,1H),2.30(s,6H),2.23-2.19(m,1H),1.99(d,J=13.3Hz,1H),1.88(s,3H).LCMS(ESI,m / z):551.85[M+H] + .
[0195] The compounds listed in Table 8 were prepared by referring to the method of Example 9. The characterization data of these compounds are listed in Table 8.
[0196] Table 8
[0197] Biological test evaluation
[0198] Test Example 1 Human CB1 ligand receptor binding assay
[0199] The affinity of the compounds of the present invention for human CB1 receptors was detected using a radioisotope-labeled ligand receptor binding assay. The compound was diluted with DMSO to a 100X concentration. 95 μL of assay buffer (25 mM Hepes, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA, pH 7.4) was added to a 96-well deep-well assay plate, followed by the addition of 5 μL of 100X compound to the corresponding wells, and the mixture was shaken at 600 rpm for 5 minutes. 300 μL of a mixture of human CHO-CB1 cell membrane and assay buffer (0.75 μL membrane and 299.25 μL assay buffer) was added to each well, and the mixture was shaken at 600 rpm for 5 minutes. 100 μL of 5X concentration of isotope [ 3 [H]-CP55940 was added to each well, centrifuged at 1000 rpm for 1 minute, and then shaken at 600 rpm for 5 minutes to mix. The plate was then incubated at 30°C for 1.5 hours. A UNIFILTER-96GF / C plate, which had been incubated at 4°C for 1 hour with 0.5% PEI solution, was washed twice with 50 mL of wash buffer (50 mM Tris-HCl, 2.5 mM EDTA, 5 mM MgCl2, 0.5 mg / ml BSA, pH 7.4). The reaction mixture in the 96-well deep-well plate was transferred to a UNIFILTER-96GF / C plate and washed four times with 900 μL of wash buffer per well. The washed UNIFILTER-96GF / C plate was dried in a 55°C oven for 10 minutes. 40 μL of ULTIMA GOLD scintillation fluid was added to each well of the dried UNIFILTER-96GF / C plate, and data were collected using a Microbeta2. The entire reaction system is 500 μL. 3 The final concentration of [H]-CP 55940 was 0.5 nM, and the final concentration of DMSO was 1%.
[0200] Use the nonlinear four-parameter equation of XLfit or GraphPad Prism software to generate the dose-effect curve of the compound and calculate its corresponding IC 50 value.
[0201] The compounds of the present invention have good binding ability to human CB1 receptors. The binding data of some compounds are shown in Table 9 below.
[0202] Table 9
[0203] Test Example 2 CB1 and CB2 cAMP generation function experiment
[0204] Flp-In-CHO human CB1 / 2, Flp-In-CHO mouse CB1 / 2, and Flp-In-CHO rat CB1 / 2 cells were cultured in complete F12K medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 600 μg / ml hygromycin at 37°C in a 5% CO2 incubator. On the day of the experiment, cells were digested and resuspended in HBSS-based assay buffer containing 20 mM HEPES, 0.1% BSA, and 500 μM IBMX. The cells were then seeded into 384-well cell culture plates. The seeding density for human and mouse CB1 / 2 cells was 8,000 cells per well, while the seeding density for rat CB1 / 2 cells was 2,000 cells per well in a 15 μL seeding volume. Compounds were then tested for their inverse agonist activity at human CB1 and CB2 receptors using a cAMP production assay.
[0205] Human CB1 inverse agonist experiment:
[0206] Add 2.5 μL of 8X compound working solution to the cell assay plate and incubate at 37°C for 10 minutes. Then, add 2.5 μL of 8X forskolin solution and incubate at 37°C for 30 minutes. After the reaction is complete, add 10 μL of Eu-cAMP tracer and 10 μL of Ulight-anti-cAMP detection reagent to the plate. Incubate at room temperature for 1 hour before collecting data using the Envision HTRF function module. The total reaction volume is 20 μL, with a final DMSO concentration of 0.2% and a final forskolin concentration of 1 μM.
[0207] Use the nonlinear four-parameter equation of XLfit or GraphPad Prism software to generate the dose-effect curve of the compound and calculate its corresponding IC 50 value.
[0208] The compounds of the present invention exhibit good human CB1 inverse agonist activity. The human CB1 inverse agonist activity of some of the compounds is shown in Table 10 below.
[0209] Table 10
[0210] Human CB2 inverse agonist experiment:
[0211] Add 2.5 μL of 8X compound working solution to the cell assay plate and incubate at 37°C for 10 minutes. Then, add 2.5 μL of 8X forskolin solution and incubate at 37°C for 30 minutes. After the reaction is complete, add 10 μL of Eu-cAMP tracer and 10 μL of Ulight-anti-cAMP detection reagent to the plate. Incubate at room temperature for 1 hour before collecting data using the Envision HTRF function module. The total reaction volume is 20 μL, with a final DMSO concentration of 0.2% and a final forskolin concentration of 2 μM.
[0212] Use the nonlinear four-parameter equation of XLfit or GraphPad Prism software to generate the dose-effect curve of the compound and calculate its corresponding IC 50 value.
[0213] The exemplary compounds of the present invention showed good selectivity for human CB2 inverse agonism. The human CB2 inverse agonist activities of some of the compounds are shown in Table 11 below.
[0214] Table 11
[0215] In contrast, the following reference compounds obtained the results shown in Table 12 below under the same conditions as above:
[0216] Table 12
[0217] It can be seen that the exemplary compounds of the present invention are significantly superior to the reference compounds in terms of selectivity for CB1 / CB2.
[0218] The above describes the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.
Claims
1. A compound of formula I, its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt, or prodrug thereof, in, X is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 6-20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group; Ra are independently selected from oxo (=O), CN, halogen, amino, nitro, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynyl; n is 1 or 2; Ring A is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rb: C 6-20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkenyl C 6-20 Aryl, 3-20 membered heterocyclic group and C 6-20 aryl; Rb are independently selected from CN, amino, nitro, halogen, C 1-12 Alkyl, halogenated C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 alkoxy; Z is N, CH or C; --Y-- is absent or represents an ethenylene group optionally substituted with Rb, provided that, when Z is N or CH, --Y-- is absent; R 1 Selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc: C6- 20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic group; Rc are independently selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogen, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 3-20 Cycloalkyl, CN, amino, nitro; R 2 Indicates -NHRd, and Rd independently represent H, unsubstituted or carboxy-substituted C 1-12 Alkyl, C 1-12 Alkylamino, amino, nitro, CN, C 1-12 Alkylcarbonylamino.
2. The compound according to claim 1, characterized in that X is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group; Ra is independently selected from ═O, CN or C 1-6 alkyl; n is 1 or 2; Ring A is selected from the following ring systems which are unsubstituted or optionally substituted with one, two or more Rb: C 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Cycloalkenyl C 6-12 Aryl, 3-12 membered heterocyclic group and C 6-12 aryl; Rb is selected from halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 alkoxy; Z is N, CH or C; --Y-- represents absence or represents vinylene optionally substituted by Rb, provided that, when Z is N or CH, --Y-- does not exist; R 1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc: C 6-12 Aryl, 5-12 membered heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, 5-12 membered heteroaryl and C 6-12 Aryl, 3-12 membered heterocyclic group and C 6-12 aryl; Rc are independently selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogen, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 3-20 Cycloalkyl, CN; R 2 Can represent -NHRd, and / or Rd independently represent H, unsubstituted or carboxy-substituted C 1-6 Alkyl, C 1-6 Alkylamino, amino, nitro, CN, C 1-6 Alkylcarbonylamino.
3. The compound according to claim 1 or 2, characterized in that In the compound represented by Formula I, the carbon atom connected to X is a chiral carbon atom, and thus the compound represented by Formula I has the structure represented by Formula Ia or Formula Ib below: Among them, X, ring A, n, Z, --Y--, R 1 、R 2 As defined in claim 1 or 2.
4. The compound according to any one of claims 1 to 3, characterized in that In the compound represented by Formula I, n is 1 or 2, --Y-- is absent, and Z is N. Therefore, the compound represented by Formula I has the structure represented by the following Formula Ic or Formula Id: Among them, X, ring A, R 1 、R 2 As defined in claims 1 to 3; Alternatively, in the compound represented by Formula I, n is 1, --Y-- represents a vinylene group optionally substituted by Rb, and Z is C, so the compound represented by Formula I has the structure represented by the following Formula Ie: Among them, X, Rb, R 1 、R 2 As defined in claims 1-3, ring A' represents C 3-20 Cycloalkyl ring or 3-20 membered heterocyclic ring, m represents 0, 1, 2 or 3.
5. The compound according to claim 4, characterized in that In the compound represented by Formula 1e, Rb replaces the ring A', so the compound represented by Formula 1e has the structure represented by the following Formula If: Among them, X, Rb, R 1 、R 2 , Ring A' and m are as defined in claim 4; Preferably, in the compound represented by Formula If, ring A' is a benzene ring, and Rb replaces ring A', so the compound represented by Formula If has the structure represented by the following Formula Ig: Among them, X, Rb, R 1 、R 2 and m as defined in claim 4 or 5.
6. The compound according to any one of claims 1 to 5, characterized in that X is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: phenyl, cyclohexyl, pyridyl, dihydropyridyl; Ra independently represents oxo, CN, C 1-6 Alkyl (eg methyl or ethyl); preferably, X is selected from phenyl, cyclohexyl, pyridin-2-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl or 4-cyanophenyl; Ring A is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rb: five-membered or six-membered heteroaryl, phenyl, 2,3-dihydro-1H-indenyl, 2,3-dihydrobenzofuranyl; Rb are independently C 1-6 Alkyl, C 1-6 Alkoxy, halogen or halogenated C 1-6 Preferably, ring A is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rb: pyridyl, pyrimidinyl, phenyl, 1H-imidazolyl, thiazolyl, 2,3-dihydro-1H-indenyl, 2,3-dihydrobenzofuranyl; Rb are each independently fluorine, chlorine, difluoromethyl, trifluoromethyl, methyl, methoxy; More preferably, ring A is selected from 5-chloropyridin-2-yl, 5-methylpyridin-2-yl, 6-methylpyridin-3-yl, 3-fluoro -5-chloropyridin-2-yl, 5-chloropyrimidin-2-yl, 6-difluoromethylpyridin-3-yl, 6-trifluoromethylpyridin-3-yl, 5-trifluoromethylpyridin-2-yl, 3-chloropyridin-6-yl, phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 1-methyl-2-trifluoromethyl-1H-imidazol-4-yl, 2-trifluoromethylthiazol-5-yl, 2,3-dihydro-1H-inden-5-yl, 2,3-dihydrobenzofuran-5-yl; R 1 selected from 4-chlorophenyl, 4-fluorophenyl, 4-cyclopropylphenyl, 4-cyanophenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-fluoro-3-trifluoromethylphenyl, 4-difluoromethylphenyl, 4-trifluoromethoxyphenyl, 4-tert-butylphenyl, 6-trifluoromethylpyridin-3-yl, 6-methoxypyridin-3-yl, 5-trifluoromethylpyridin-2-yl, 6-chloropyridin-3-yl, 3-trifluoromethylbicyclo[1.1.1]pentan-1-yl, 1-ethyl-1H-pyrazol-4-yl, 2-trifluoromethylthiazol-5-yl, 2,3-dihydrobenzofuran-5-yl, pyrazolo[1,5-a]pyridin-5-yl; R 2 Indicates -NHRd, wherein Rd independently represents H, unsubstituted C 1-6 Alkyl, amino, C 1-6 Alkylcarbonylamino, carboxyl C 1-12 alkyl; Preferably, Rd independently of one another represent H, methyl, amino, acetylamino, 2-carboxymethyl-4-methylpentan-1-yl, pivaloylamino.
7. The compound according to any one of claims 1 to 6, characterized in that The compound represented by formula I is selected from the following compounds:
8. A pharmaceutical composition, characterized in that Including at least one of the compound represented by formula I according to any one of claims 1 to 7, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof; Preferably, the pharmaceutical composition further comprises one, two or more pharmaceutically acceptable excipients.
9. The pharmaceutical composition according to claim 8, characterized in that The pharmaceutical composition is used for preventing or treating diseases or conditions mediated by cannabinoid receptor type 1 (CB1). Preferably, the cannabinoid receptor mediated disease or disorder is selected from the group consisting of obesity, PWS syndrome, diabetes, non-alcoholic steatohepatitis, fibrosis, diabetic nephropathy, diabetic gastroparesis, tobacco dependence, and high cholesterol.
10. Use of a compound of formula I according to any one of claims 1 to 7, its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition according to claim 8 or 9 in the preparation of a medicament for treating or preventing cannabinoid receptor-mediated disorders.
Citation Information
Patent Citations
Amidine and guanidine derivatives, preparation method therefor and medical uses thereof
CN111630048A
Tetrahydropyridazine compound, composition containing tetrahydropyridazine compound and application of tetrahydropyridazine compound
CN118414329A
Cannabinoid receptor mediating compounds
WO2016196646A1
